Search

Jere E Meredith

from Haddam, CT
Get Report
Also known as:
Jere E Merideth, Jere Garnetvalle Meredith, Jere J Meredith, Jerry Meridith
Phone and address:
102 Hayden Hill Rd, Haddam, CT 06438
(860) 345-4689
Connected to:
Alaina N Meredith, 41Alexis Meredith, 37Audie R Meredith, 72Betsy L Meredith, 72Beverly Meredith, 59Bobbi J Meredith, 54Bobby L Meredith, 40Bonita C Meredith, 49Brandie Meredith, 31Brent M Meredith, 47

Jere Meredith Phones & Addresses

  • 102 Hayden Hill Rd, Haddam, CT 06438 (860) 345-4689
  • 1078 Ryans Run, Marcus Hook, PA 19061 (610) 497-0032
  • Garnet Valley, PA
  • Payne, GA
  • 70 Point Arrowhead Rd, Guilford, CT 06437
  • 7210 Calle Cristobal, San Diego, CA 92126 (858) 695-0321
  • Wilmington, DE

Resumes

Resumes

Jere Meredith Photo 1

Senior Principal Scientist At Bristol-Myers Squibb

View page
Position:
Senior Principal Scientist, CNS at Bristol-Myers Squibb
Location:
Wallingford, Connecticut
Industry:
Pharmaceuticals
Work:
Bristol-Myers Squibb - Wallingford, CT since Jan 2008
Senior Principal Scientist, CNS
Bristol-Myers Squibb - Wallingford, CT Jan 2002 - Jan 2008
Principal Scientist, CNS
Bristol-Myers Squibb Jan 2001 - Jan 2002
Senior Research Investigator II
DuPont Pharmaceuticals Company Jan 1999 - Jan 2001
Senior Research Scientist
Scripps Research Institute Jan 1992 - Jan 1999
Post Doc Research Associate
Education:
University of Illinois at Chicago 1986 - 1992
Ph.D, Biochemistry University of Michigan
B.S.E, Chemical Engineering
Jere Meredith Photo 2

Jere Meredith

View page

Publications

Us Patents

Gamma Secretase Notch Biomarkers

View page
US Patent:
7989208, Aug 2, 2011
Filed:
Sep 2, 2009
Appl. No.:
12/552361
Inventors:
Rex Denton - Madison CT, US
Jere E. Meredith - Haddam CT, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
G01N 33/483
G01N 33/50
G01N 33/53
C07K 14/435
A61K 38/00
US Classification:
436 63, 436 86, 436501, 435 71, 435 792, 514 1, 514 11, 530350
Abstract:
The present invention relates to the biomarker TFF-3 that measures γ-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by γ-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.

Method Of Generating A Dosing Schedule Using Gamma Secretase Notch Biomarkers

View page
US Patent:
8206989, Jun 26, 2012
Filed:
Jun 22, 2011
Appl. No.:
13/166103
Inventors:
Rex Denton - Madison CT, US
Jere E. Meredith - Haddam CT, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
G01N 33/483
G01N 33/50
G01N 33/53
C07K 14/435
A61K 38/00
US Classification:
436 63, 436 86, 436501, 435 71, 435 792, 514 1, 514 11, 530350
Abstract:
The present invention relates to the biomarker TFF-3 that measures γ-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by γ-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.

Methods For Use For Integrin B1C Cell Growth Inhibitor

View page
US Patent:
20020102240, Aug 1, 2002
Filed:
Apr 12, 1999
Appl. No.:
09/291144
Inventors:
MARTIN A. SCHWARTZ - POWAY CA, US
JERE E. MEREDITH - SAN DIEGO CA, US
YOSHIKAZU TAKADA - SAN DIEGO CA, US
LUCIA LANGUINO - MILFORD CT, US
International Classification:
A61K048/00
C12N015/00
C12P021/02
C12N005/08
US Classification:
424/093210, 514/044000, 435/455000, 435/320100, 435/325000, 435/069100
Abstract:
The present invention provides a method for inhibiting cell proliferation in a cell comprising contacting the cell with a nucleic acid sequence or a polypeptide having essentially the sequence of the integrin. Also included in the invention are peptides consisting of amino acid residues which are the size of or fewer than the sequence of the cytoplasmic domain of the integrin consisting essentially of the amino acid sequence of SEQ ID NO:1 and SEQ ID NO:2, and functional fragments thereof which are useful for inhibiting cellular proliferation. Peptides, polynucleotides, and antibodies immunoreactive with the peptides, and methods of use for inhibiting cell growth are also provided.

Gamma Secretase Notch Biomarkers

View page
US Patent:
20070072227, Mar 29, 2007
Filed:
Sep 26, 2006
Appl. No.:
11/526995
Inventors:
Jere Meredith - Haddam CT, US
Craig Polson - Middletown CT, US
International Classification:
C12Q 1/68
G01N 33/53
G06F 19/00
US Classification:
435006000, 435007920, 702019000, 702020000
Abstract:
The present invention relates to biomarker indicators, including polypeptides, polynucleotides and small molecules, that measure γ-secretase mediated Notch processing. These indicators have utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by γ-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as GI cellular damage.

Gamma Secretase Notch Biomarkers

View page
US Patent:
20080020395, Jan 24, 2008
Filed:
Jul 18, 2007
Appl. No.:
11/779306
Inventors:
Rex Denton - Madison CT, US
Jere E. Meredith - Haddam CT, US
International Classification:
C12Q 1/37
C12Q 1/68
US Classification:
435 6, 435 23
Abstract:
The present invention relates to the biomarker TFF-3 that measures γ-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by γ-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.

Methods Of Use For Integrin B.sub.1C Cell Growth Inhibitor

View page
US Patent:
6013495, Jan 11, 2000
Filed:
Oct 14, 1997
Appl. No.:
8/951200
Inventors:
Martin A. Schwartz - Poway CA
Jere E. Meredith - San Diego CA
Yoshikazu Takada - San Diego CA
Lucia Languino - Milford CT
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C12N 138
C12N 1300
C07K 708
C07K 14435
US Classification:
4351731
Abstract:
The present invention provides a method for inhibiting cell proliferation in a cell comprising contacting the cell with a nucleic acid sequence or a polypeptide having essentially the sequence of the. beta. sub. 1C integrin. Also included in the invention are peptides consisting of amino acid residues which are the size of or fewer than the sequence of the cytoplasmic domain of the. beta. sub. 1C integrin consisting essentially of the amino acid sequence of SEQ ID NO:1 and SEQ ID NO:2, and functional fragments thereof which are useful for inhibiting cellular proliferation. Peptides, polynucleotides, and antibodies immunoreactive with the peptides, and methods of use for inhibiting cell growth are also provided.
Control profile
Jere E Meredith from Haddam, CT Get Report